Phaseline

Companies › Kardigan

Kardigan: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
danicamtiv
Cardiac myosin activator
MYH7, MYH6, MYH7B, MYL3, MYL2Phase 3Symptomatic Genetic Dilated Cardiomyopathy (DCM); Symptomatic Genetic Dilated CardiomyopathySep 2027
Tonlamarsen
Antisense oligonucleotide targeting ALOX5AP; reduces leukotriene production to lower blood
ALOX5APPhase 2HypertensionDec 2026
Ataciguat
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Moderate Aortic Valve StenosisAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07511361TonlamarsenPhase 2HypertensionCardiovascularDec 2026
NCT07210723danicamtivPhase 2Symptomatic Genetic Dilated CardiomyopathyCardiovascularSep 2027
NCT07001800AtaciguatPhase 2Moderate Aortic Valve StenosisCardiovascularAug 2028
NCT07771465danicamtivPhase 3Symptomatic Genetic Dilated Cardiomyopathy (DCM)CardiovascularNov 2032

From the company's SEC filings

Cash and short-term investments of $661m on 2026-06-30; operating cash outflow about $218m a year; runway about 36 months at that burn, to Jul 2029; 3 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ALOX5AP (1) GUCY1B1 (1) GUCY1A2 (1) GUCY1A1 (1) MYH7 (1) MYH6 (1) MYH7B (1) MYL3 (1) MYL2 (1)

Companies with the same targets

Merck & Co. (MSD) Bayer Akebia Therapeutics Pulmovant Coherus Oncology Bristol-Myers Squibb Cytokinetics

Companies built like this

Cytokinetics Tectonic Therapeutic Pulmovant Inhibikase Therapeutics Thryv Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.